Global Hematology Testing Instrument Market Driven by Growing Demand for Preventive Diagnosis and Treatment Monitoring
|
By LabMedica International staff writers Posted on 26 Aug 2021 |

Illustration
The global hematology testing instrument market is witnessing high growth due to technological advances in disease diagnosis and rise in demand for preventive diagnosis and treatment monitoring.
These are the latest findings of Transparency Market Research (Albany, NY, USA), a next-generation market intelligence provider.
Hematology involves the study of blood, in particular how blood can affect overall health. Used in different settings, hematology instruments can do blood count, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. Hematology tests can evaluate a number of blood conditions including infection, anemia, inflammation, hemophilia, blood-clotting disorders, leukemia, and the body’s response to chemotherapy treatments. Tests could be routine and regular, or these may be used to diagnose serious conditions in urgent situations.
Hematology testing devices have come a long way from disease detection and monitoring to counting and characterizing blood cells. The concept of automation has extended to detecting small cell populations to diagnose rare blood conditions, which require less labor, rapid result, and easy-to-use analyzers. Current technologies include automation of hematology analyzers, electrical impedance, flow cytometry, and fluorescent flow. The combination of these technologies has increased the yield and productivity of test results. Test volume i.e., number of tests performed, is projected to increase owing to technological advances in disease diagnosis and rise in demand for preventive diagnosis and treatment monitoring. This will also augment the demand for hematology analyzers with high throughput. Such technological revolutions in hematology testing are expected to propel the market growth during the forecast period.
However, technological advancements in blood testing instruments carry a heavy price tag. A number of laboratories cannot afford highly priced instruments. Therefore, there is a need of low-volume laboratory analyzers, which are cost-effective and easy-to-use. The high cost of instruments can increase testing cost, which can restrain the growth of the global hematology diagnostic market during the forecast period.
Geographically, North America is projected to dominate the global hematology diagnostic market during the forecast period. This can be attributed to the high average selling price of automated hematology analyzers, rise in demand among surgeons for technologically-advanced diagnostic instruments with enhanced specificity & precision, and favorable coverage as per the Clinical Laboratory Improvement Amendments for in-vitro diagnostic procedures in the region.
Related Links:
Transparency Market Research
These are the latest findings of Transparency Market Research (Albany, NY, USA), a next-generation market intelligence provider.
Hematology involves the study of blood, in particular how blood can affect overall health. Used in different settings, hematology instruments can do blood count, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. Hematology tests can evaluate a number of blood conditions including infection, anemia, inflammation, hemophilia, blood-clotting disorders, leukemia, and the body’s response to chemotherapy treatments. Tests could be routine and regular, or these may be used to diagnose serious conditions in urgent situations.
Hematology testing devices have come a long way from disease detection and monitoring to counting and characterizing blood cells. The concept of automation has extended to detecting small cell populations to diagnose rare blood conditions, which require less labor, rapid result, and easy-to-use analyzers. Current technologies include automation of hematology analyzers, electrical impedance, flow cytometry, and fluorescent flow. The combination of these technologies has increased the yield and productivity of test results. Test volume i.e., number of tests performed, is projected to increase owing to technological advances in disease diagnosis and rise in demand for preventive diagnosis and treatment monitoring. This will also augment the demand for hematology analyzers with high throughput. Such technological revolutions in hematology testing are expected to propel the market growth during the forecast period.
However, technological advancements in blood testing instruments carry a heavy price tag. A number of laboratories cannot afford highly priced instruments. Therefore, there is a need of low-volume laboratory analyzers, which are cost-effective and easy-to-use. The high cost of instruments can increase testing cost, which can restrain the growth of the global hematology diagnostic market during the forecast period.
Geographically, North America is projected to dominate the global hematology diagnostic market during the forecast period. This can be attributed to the high average selling price of automated hematology analyzers, rise in demand among surgeons for technologically-advanced diagnostic instruments with enhanced specificity & precision, and favorable coverage as per the Clinical Laboratory Improvement Amendments for in-vitro diagnostic procedures in the region.
Related Links:
Transparency Market Research
Latest Industry News
- New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
- Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
- Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
- Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
- Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer
- Global Urinalysis Market Gowth Driven by Demand for Automated and POC Testing
- New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
- New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
- AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
- Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
- Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
- Standardized Staining Technology Advances Digital Pathology Workflows
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
- Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing
- Collaboration Explores Clinical Use of Single-Cell and Spatial Technologies
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read moreMolecular Diagnostics
view channel
Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
Molecular laboratories are under pressure to detect extremely low levels of residual disease, yet pre-analytical recovery of cell-free and genomic DNA from large-volume blood and plasma remains a persistent... Read more
New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
Plasma-based liquid biopsy can miss clinically actionable tumor signals, particularly in early-stage disease and low-shedding tumors, limiting its utility for routine monitoring. Clinical laboratories... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read morePathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read moreTechnology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more





.jpg)

